Compare Adaptive Biotechnologies Corp (ADPT) vs JD.Com Inc (JD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs JD.Com Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while JD.Com Inc trades at $27.63 (market cap $36.37B). The key difference: JD.Com Inc is far larger — about 10.9× Adaptive Biotechnologies Corp's market cap, and JD.Com Inc pays a 3.78% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | JD | |
|---|---|---|
Market Cap | $3.33B | $36.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $36.17 |
52-Week Low | $10.24 | $25.19 |
Enterprise Value | $3.19B | $22.53B |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
JD trades at $26.49, down 0.49% on the day, with a bearish technical signal and mixed sentiment. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 show operational strength, but net income margin compression to 1.05% in 2025 raises concerns. The stock appears undervalued with a P/S of 0.2 and P/E of 19.66, while analyst consensus remains strongly bullish with a $39.20 price target.
The outlook is cautiously optimistic given JD's low valuation and consistent earnings outperformance, but risks include legal investigations, margin pressure, and macroeconomic headwinds. Upside potential exists if the company can sustain revenue growth and improve profitability, though near-term volatility may persist due to negative news flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
